Stage set for Jardiance to become universal heart failure drug
pharmaphorum
MARCH 3, 2022
The findings – published today in the journal Nature Medicine – come after Jardiance was approved for chronic heart failure with reduced ejection fraction (HFrEF) last year, with the label expanded to include patients with heart failure with preserved ejection fraction (HFpEF) last month. It has been used to treat type 2 diabetes since 2014.
Let's personalize your content